NCDEU 2010: Featured Speakers

Learning from the Past to Advance the Future of Mental Health Treatment Plenary Session Topics and Speakers
Clinical Research in Schizophrenia: Where Have We Been and Where Are We Going John M. Kane, M.D. The Zucker Hillside Hospital and Albert Einstein College of Medicine John M. Kane, M.D., is Vice President for Behavioral Health Services of the North Shore - Long Island Jewish Health System and Chairman of Psychiatry at The Zucker Hillside Hospital. He is Professor of Psychiatry, Neurology and Neuroscience and holds the Dr. E. Richard Feinberg Chair in Schizophrenia Research at the Albert Einstein College of Medicine. Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine. He currently directs the NIMH-funded Advanced Center for Interventions and Services Research in Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the Council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration. Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.
Randomized Clinical Trial Design: 50 Years of Learning from Mistakes Helena C. Kraemer, Ph.D. Stanford University Dr. Kraemer’s research focuses on methods used in research in the behavioral aspects of medicine, both experimental and observational studies. For the most part, her work has focused on psychiatry and health psychology, but as behavior has become of increasing interest in all other fields of medicine, in cardiology, in epidemiology, in pediatrics, in oncology as well, her focus has widened as well. Her more recent work has focused on effect sizes that convey clinical significance, on moderators and mediators of treatment in randomized clinical trials, on improving statistical methods in epidemiology, and on systemic changes to foster more reproducible, more cost-effective research. Current position: Professor of Biostatistics in Psychiatry (Emerita), Department of Psychiatry and Behavioral Sciences, Stanford University and Department of Psychiatry, University of Pittsburgh.
Developing Novel Therapeutics for Severe Neuropsychiatric Disorders: The Way Forward During Very Challenging Times Husseini K. Manji, M.D., F.R.C.P.C. Johnson & Johnson Pharmaceutical Research and Development, LLC Husseini K. Manji, M.D., is Global Therapeutic Head, Neuroscience, Johnson and Johnson Pharmaceutical Research and Development. He was previously Chief, Laboratory of Molecular Pathophysiology and Experimental Therapeutics, NIMH, and Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following residency training, he completed fellowship training at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK. The major focus of his research has been the investigation of disease-and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. He has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. Dr. Manji has been the recipient of numerous awards and inducted into the National Academy of Sciences’ Institute of Medicine (IOM), is a Councilor of both the ACNP and Society of Biological Psychiatry, chaired the ACNP’s Task Force on New Medication Development, and is immediate past president of the Society of Biological Psychiatry.
In the Beginning... George M. Simpson, M.D. USC Keck School of Medicine George Simpson, M.D., is currently Professor of Research Psychiatry at the Keck School of Medicine, University of Southern California. He belongs to numerous organizations and has held a variety of positions in the American College of Neuropsychopharmacology, including serving as President in 1992. Dr. Simpson has been a consultant for the FDA and participated on National Institute of Mental Health grant review panels focusing on treatment assessment, serving as reviewer and chairperson. He is an honorary Fellow of the Royal College of Psychiatrists. He won the Arthur P. Noyes Award for outstanding contributions in the field of schizophrenia in 1991, and received an Honorary Doctor of Medicine from the University of Goetberg in Sweden in 1994 and the Heinz E. Lehman Research Award in 1999 for outstanding contribution to research. He was elected Honorary President of the Egyptian Psychiatric Association in 2003. Dr. Simpson has published widely in the field of schizophrenia and depression.

Keynote Speaker
The Genetics of Schizophrenia and Bipolar Disorder - Implications for Treatment Development Edward M. Scolnick, M.D. Broad Institute Edward Scolnick, M.D., is Director of the Psychiatric Disease Program and the Stanley Center for Psychiatric Research at the Broad Institute and a Senior Associate Member. He works closely with principal investigator Pamela Sklar towards identifying risk genes for bipolar disorder and schizophrenia. From 1982-2003, Dr. Scolnick served as President of Merck Research Laboratories; Executive Vice President for Science and Technology at Merck & Company, Inc; Executive Director and Vice President in the Department of Virus and Cell Biology and Senior Vice President for basic research at Merck Research Laboratories. Prior to joining Merck, he worked at the National Cancer Institute where he demonstrated the cellular origin of sarcoma virus oncogenes in mammals and defined specific genes that cause human cancer. He also worked at the National Heart, Lung and Blood Institute where his work defined the stop signals in the genetic code and the biochemical mechanism that produces the stops. Dr. Scolnick was elected to the National Academy of Sciences in 1984 and to the American Academy of Arts and Sciences in 1993. He became a member of the Institute of Medicine in 1996. Among his many other academic honors, he was selected as Regents’ Lecturer, University of California at Berkeley, Frank H.T. Rhodes Class of ‘56 University Professor at Cornell University, and appointed to the Board of Visitors at the University of Pittsburgh School of Medicine. He served on the Board of Directors of Merck & Co., Inc. from 1997 to 2002, as a member of the National Advisory Mental Health Council for the National Institute of Mental Health from 1999 to 2002, and the FDA Science Board from 2000 to 2002. He currently is a consultant for Clarus Ventures and Charles River Laboratories and serves on the Board of Directors for Millipore Corporation and McLean Hospital. Dr. Scolnick holds an A.B. from Harvard College and an M.D. from Harvard University Medical School.
NIMH Plenary Session Speakers
NIMH Extramural Program Update Philip S. Wang, M.D., Dr.P.H. National Institute of Mental Health Dr. Philip S. Wang is the Deputy Director of NIMH. A psychiatrist, he had been director of NIMH’s Division of Services and Interventions Research (DSIR) since 2006. Before joining NIMH in 2006, Dr. Wang was on the faculty at Harvard Medical School in psychiatry and health care policy, where he was an NIMH grantee and one of the nation’s leaders in health services research and the economics and epidemiology of medication treatment. Dr. Wang is a recipient of the American Psychiatric Association’s Health Services Research Scholar Award and is one of the most highly cited scientists in areas as diverse as depression in the workplace and noncompliance with anti-hypertensive medications. Dr. Wang completed his undergraduate, medical school, psychiatry residency as well as master’s and doctoral training in epidemiology at Harvard University. He was principal investigator of the NIMH-sponsored Work Outcomes Research and Cost-effectiveness Study, a large-scale trial to examine the return-on-investment of enhanced depression care for workers. He also served as a voting member on FDA’s psychopharmacologic and endocrinologic and metabolic drugs advisory committees, its neurological devices panel and on the NIMH services research and clinical epidemiology study section. He currently chairs the WHO world mental health study services research work group. Dr. Wang is an author of approximately 150 scientific publications.
NIMH Intramural Program Update Richard K. Nakamura, Ph.D. National Institute of Mental Health Dr. Richard K. Nakamura is the Scientific Director of the National Institute of Mental Health (NIMH). In that capacity, he leads the in-house research program of the NIMH. Dr. Nakamura received his Bachelor of Arts in Psychology from Earlham College (Richmond, IN), and his Ph.D. in Psychology from State University of New York (Stony Brook, NY). He has been with the NIMH since 1976, and since 1997, has served as Acting Deputy Director (1997-1999), Deputy Director (1999-2008) and Acting Director (2001-2002). While at NIMH, he has held other positions such as Associate Director for Science Policy and Program Planning; Chief, Behavioral and Integrative Neuroscience Research Branch; and Coordinator, ADAMHA Office of Animal Research Issues. In 1999, Dr. Nakamura led the NIH/NIMH participation with the U.S. Surgeon General's Office in the first report on mental illness. Dr. Nakamura received recognition from the Secretary of the Department of Health and Human Services for his leadership in the Secretary’s Initiative in Mental Health, and for the Surgeon General’s Report on Mental Health. In 2001, he received the NIH-Asian/Pacific American Organization (APAO) Outstanding Achievement Award for Administrative Work. In 2002, Dr. Nakamura was elected by the American Association for the Advancement of Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded the Presidential Rank Award for outstanding leadership. In 2004 and 2005 respectively, he received leadership awards from the Federation of Behavioral Psychological and Cognitive Sciences, and from the International Society for Behavioral Neuroscience. In 2009 he was awarded the NIH Director’s Award for Outstanding Administration.

Get Acrobat reader...